Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Kraynak

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
American Pharmacy|December 1, 1994
The women's health movement: political, social, and medical issuesM A Kraynak
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|January 22, 1998
Pharmaceutical aspects of docetaxelM A Kraynak
The Annals of Pharmacotherapy|December 1, 1994
Twice-daily cefaclor therapyS T Haines, M A Kraynak
American Pharmacy|April 1, 1995
Sexually transmitted diseases: an updateM A Kraynak, L C Knodel
Formulary (Cleveland, Ohio)|October 5, 1995
Adapting a commercially available software program to improve ADR reportingA J Ries, M A Kraynak
Pharmacotherapy|November 5, 1997
A statistical and clinical evaluation of fingerstick and routine laboratory prothrombin time measurementsH I Bussey, E Chiquette, T M Bianco, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 1998
Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumorsM L Rothenberg, A Sharma, G R Weiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumorsR L Drengler, J G Kuhn, L J Schaaf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumorsS G Eckhardt, J Rizzo, K R Sweeney, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
American Pharmacy|December 1, 1994
The women's health movement: political, social, and medical issuesM A Kraynak
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|January 22, 1998
Pharmaceutical aspects of docetaxelM A Kraynak
The Annals of Pharmacotherapy|December 1, 1994
Twice-daily cefaclor therapyS T Haines, M A Kraynak
American Pharmacy|April 1, 1995
Sexually transmitted diseases: an updateM A Kraynak, L C Knodel
Formulary (Cleveland, Ohio)|October 5, 1995
Adapting a commercially available software program to improve ADR reportingA J Ries, M A Kraynak
Pharmacotherapy|November 5, 1997
A statistical and clinical evaluation of fingerstick and routine laboratory prothrombin time measurementsH I Bussey, E Chiquette, T M Bianco, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 1998
Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumorsM L Rothenberg, A Sharma, G R Weiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumorsR L Drengler, J G Kuhn, L J Schaaf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumorsS G Eckhardt, J Rizzo, K R Sweeney, et al.
Pageof 1